OncXerna Therapeutics
OncXerna Therapeutics is a clinical-stage precision oncology biotech developing RNA-based biomarker-guided bispecific antibody therapies for cancer patients, headquartered in Waltham, Massachusetts and incorporated in the Cayman Islands.
- Company typePrivate
- Founded2018
- HeadquartersWaltham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
OncXerna Therapeutics firmographics
Firmographics- Name
- OncXerna Therapeutics
- Legal name
- OncXerna Therapeutics, Ltd.
- Website
- https://oncxerna.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- OncXerna Therapeutics is a clinical-stage precision oncology biotech developing RNA-based biomarker-guided bispecific antibody therapies for cancer patients, headquartered in Waltham, Massachusetts and incorporated in the Cayman Islands.
- Ownership category
- akta.pro rank
OncXerna Therapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)
Keywords
Where OncXerna Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OncXerna Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
OncXerna Therapeutics product offering
Product offeringCore offering
OncXerna Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer treatment. The company's pipeline is enabled by its proprietary RNA-based biomarker platform that informs precision medicine approaches for oncology patients. The firm operates as a privately held, for-profit pharmaceutical entity headquartered in Waltham, Massachusetts.
Differentiator
Problem solved
Functional benefit
Products and services
- Bispecific Antibody Therapeutics Pipeline
Companies that use OncXerna Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
OncXerna Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OncXerna Therapeutics partnerships and signals
Strategic signalScale indicators1 record
OncXerna Therapeutics competitors and assessment
Company assessmentMarket position
Customer concentration
OncXerna Therapeutics social profiles
Digital presenceOncXerna Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncXerna Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
OncXerna Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncXerna Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncXerna Therapeutics
What does OncXerna Therapeutics do?
OncXerna Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer treatment. The company's pipeline is enabled by its proprietary RNA-based biomarker platform that informs precision medicine approaches for oncology patients. The firm operates as a privately held, for-profit pharmaceutical entity headquartered in Waltham, Massachusetts.
Is OncXerna Therapeutics a public or private company?
OncXerna Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was OncXerna Therapeutics founded?
OncXerna Therapeutics was founded in 2018. It employs 11 to 50 people.
Where is OncXerna Therapeutics based?
OncXerna Therapeutics is headquartered in Waltham, United States, in the North America region.
Does OncXerna Therapeutics have an API?
No public API is recorded for OncXerna Therapeutics.
What industry is OncXerna Therapeutics in?
OncXerna Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325414.